Welcome to the Transplant Centre Biobank

Since the first organ transplant nearly half a century ago, patients are living longer after transplant than ever before. This is all thanks to the research efforts of physicians and scientists to better understand the immunologic basis of transplant and to develop more effective immunosuppressive medicines.

Despite improvements in transplant survival over the years, there remain factors that limit both survival and quality of life post-transplant. There is considerable variability between individuals in outcomes after a solid organ transplant. This includes differences in how some individuals respond to treatment, outcomes, and side-effects. The reasons for this variability are poorly understood, but a large part of these differences are likely genetic. Today, advances in technology permit us to scan the whole genome of an individual. This sophisticated technology opens new opportunities to investigate how genetic variation contributes to clinical outcomes.

This SickKids Transplant Centre research initiative has resulted in the establishment of the first pediatric cross-organ transplant biorepository in Canada. The goal is to apply knowledge of genomics and pharmacogenomics to research and practice of transplant medicine with the goal of eventually personalizing the care of these patients. Collaborations with stem cell experts will allow us to model disease to develop new therapies for end-stage organ disease. Through a cross-disciplinary approach, we hope to ultimately improve not only survival but also the quality of life for individuals after organ transplantation.

Our Biobank Family


    Our enrollment is trending up as we continue to recruit new and retain existing participants. Our patient population grows on average by 8% each year. We currently have over 9,900 participants.

  • DATA

    Data use is trending up as we have supported 50 new research studies within the past 3 years with the specimens and data that you have donated to the biobank.


    Family participation is trending up, with 370% increase within this past year. We recognize the importance of studying not just the child with disease but parents to help us determine if the finding is new or passed down. If you are a parent who has not yet participated and would like to, please contact us! Participation can aso be coordinated by mail.

Our scientific lead Dr. Seema Mital is vice-chair of important new @ACCinTouch @American_Heart guidelines on how to diagnose, treat hypertrophic cardiomyopathy: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000937

Read more about the new AHA/ACC guideline for hypertrophic cardiomyopathy, which "emphasizes the importance of incorporating patient’s lifestyle choices and preferences when making complex, life-altering decisions." https://www.mdedge.com/cardiology/article/232258/heart-failure/new-hcm-guidelines-make-shared-decision-making-top-priority

Today, our Centre turns six. We thank the Rogers family for their transformative vision and donation, which has united our teams at @SickKidsNews @UHN @UofT in a shared mission that's now yielding world-leading research and clinical innovation.

Just Published: 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
http://ow.ly/Y8Y350Ccude #AHAJournals @AHAScience

Contact Us

If you are interested in participating, have any questions, or want to find out more, please get in touch with us at anytime!